Willing to Win Reader
What biotech leaders did in your situation.
Standing on the shoulders of giants.
The conversations on Willing to Win, sorted by the situation you are in. Not by guest, not by episode. Each page holds what the people who were there said about it: how it felt, what they did the next morning, what came of it, and what to do this week. In their words.
Pick the one you are in. Below that, every conversation on its own, to read in full or to watch.
By situation
One page per situation. The first is live, the others follow one by one.
- If you are a biotech CEO and fear running out of cash before the readout.Read the guidance
- If you are a biotech CEO and the round is taking longer than the runway.In preparation
- If you are a biotech CEO and the bar for the next round has moved up since you last raised.In preparation
- If you are a biotech CEO and the readout was bad.In preparation
- If you are a biotech CEO and pharma wants the asset after phase 1, and you are not sure you should sell.In preparation
- If you are a biotech CEO and have to let people go.In preparation
- If you are a biotech CEO and the board is asking whether you are the CEO for the next phase.In preparation
- If you are a biotech CEO and the team that got you here is struggling at this size.In preparation
- If you are a biotech CEO, alone at seed, and the first investor just said no.In preparation
By conversation
Every guest, newest first. Read the full conversation, or watch it on YouTube.
Read WatchSezai Taskin
CEO, ViferaXS
The Moment You Doubt Yourself Is the Moment You Should Stop
Read WatchAchim Plum
Managing Director of HTGF (High-Tech Gründerfonds), heading Life Science and Chemistry
So, Do We Have a Deal?
Read WatchAntonin "Tony" de Fougerolles
Founding Chief Scientific Officer of Moderna; board chair and investor
I Shouldn't Be Here: Moderna's First CSO on Making Life Count
Read WatchWolfgang Hofmann
CEO, leon-nanodrugs (Munich)
I Can't Not Be Fascinated
Read WatchKarol Jarzabek
Chief Operating Officer, iOrganBio
We understand only 8 % of Biology
Read WatchRosario "Charo" Cestau Murphy
Life sciences commercial executive, Strategic Planning at Untech; formerly Biogen, Vertex and Genzyme
Turning down the obvious path
Read WatchDr. Dominik Witzigmann
Co-Founder and President of Nanovation Therapeutics
The Fight for Thousands is not over
Read WatchTilmann Bürckstümmer
Co-founder, Myllia Biotechnology
Why This CRISPR Founder Built a Biotech Without VC Money
Read WatchJan de Kerpel
Investment Banker, Managing Director Van Lanschot Kempen
The Truth About Biotech Funding Nobody Wants To Admit
Read WatchSimone Sabbione
Co-founder, Meliodays
FemTech's Trillion-Dollar Question Nobody Asked
Read WatchChris Przybyszewski
Serial biotech founder (five companies, including US Biologic)
From Shakespeare to a Biotech Exit
Read WatchMiguel Coego Rios
CFO of a major biotech company in rare diseases
What Nobody Told Me About Resilience: A CFO's Hard Warning
Read WatchKlaus Weinberger
CEO, Metaron Diagnostics; co-inventor of one of the first real-time PCR assays
Sabotaged and Still Building
Read WatchMelissa Simon
Partner, Family Office Wieland Capital
What Investors Look For in Founders: Trust, Femtech & VC Decisions
Read WatchDr. Pierre Morgon
Founder of MRGN Advisors; former EVP at CanSino Biologics and VP at Sanofi Pasteur
The Biggest Pain as a Leader? 40 Years of Hard Truths in Biotech
Read WatchPeter Seufer-Wasserthal
Chairman of the Board at Imperagen and PlanetSmart
Every Chapter Needs a Different You: The Cost of Not Transforming
Read WatchZoltan Magyarics
VP of R&D at AOP Health; physician and PhD immunologist
How The Biotech Game Breaks Your Idealism: A Drug Hunter's Confession
Read WatchErich Tauber
Co-founder and former CEO, Themis Bioscience
What Nobody Tells You About a Life-Changing Deal
Read WatchIlkka Haukijärvi
CEO who built a global vaccine CRO from scratch; former Director of HR at a Finnish university
Winning The Infinite Game: Why Great Leaders Embrace Failure
Read WatchJesper Brandgaard
Chairman of LEO Pharma and former CFO of Novo Nordisk (18 years)
Ownership Of The Downside: Elite Leaders Under Pressure
Read WatchOliver Schacht
Biotech executive and former public-company CEO; three IPOs; PhD in business
An IPO Is Just The Beginning: The Real Fight Starts When You Go Public
Read WatchEdwin Moses
Chairman Grey Wolf Therapeutics. Chairman and CEO Ablynx (until 2018)
Feeling Out Of Place. The Story Behind Edwin Moses And How Insecurity Fueled Optimism
Read WatchThaminda Ramanayake
CEO Anaveon, CBO CureVac (until 2025)
Leaving Ego Aside: Inside the BioNTech CureVac Deal
Follow the show: YouTubeSpotifyApple Podcasts
The next seat.
If you think about hiring, permanent, interim or fractional: find out which seat is due, or let's have a chat.
